Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

about

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

Item

http://www.wikidata.org/entity/Q39389346

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@en

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@nl

type

Item

label

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@en

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@nl

prefLabel

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@en

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@nl

P1476

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

@en

P2093

Bum Jun Kim

http://www.w3.org/2001/XMLSchema#string

Hyeong Su Kim

http://www.w3.org/2001/XMLSchema#string

Hyun Joo Jang

http://www.w3.org/2001/XMLSchema#string

Jung Han Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

The blockade of immune checkpoints in cancer immunotherapy

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.

P304

1460-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.18470

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28638461

http://www.w3.org/2001/XMLSchema#string

P932

5479252

http://www.w3.org/2001/XMLSchema#string